Viatris Inc. announced the launch of Gen-Clozapine orally disintegrating tablets (ODT) in Canada. This product is available in multiple strengths, including 12.5 mg, 25 mg, 50 mg, 100 mg, and 200 mg.
This launch marks the first availability in Canada of an orally disintegrating tablet formulation of clozapine. Clozapine is recognized as the only approved antipsychotic for treatment-resistant schizophrenia.
The introduction of Gen-Clozapine ODT provides a new and potentially more convenient treatment option for patients suffering from treatment-resistant schizophrenia in Canada. This expands Viatris's portfolio in mental health and leverages its expertise in complex generic formulations.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.